In Pivotal Phase III Studies, Merck’s Investigational Medicine Boceprevir Helped Majority of Patients With Chronic …

In Pivotal Phase III Studies, Merck’s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic …
WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® (peginterferon alfa …
Read more on Business Wire

Tampa Bay area health support groups
Health screenings
Read more on The Tampa Tribune